Description: ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Home Page: www.anipharmaceuticals.com
210 Main Street West
Baudette,
MN
56623
United States
Phone:
218 634 3500
Officers
| Name | Title |
|---|---|
| Mr. Nikhil Lalwani | Pres, CEO & Director |
| Mr. Stephen P. Carey | CFO, Sr. VP of Fin. & Corp. Sec. |
| Mr. James G. Marken | Sr. VP of Operations & Product Devel. |
| Mr. Christopher K. Mutz | Head of Rare Disease |
| Mr. Ori Gutwerg | Sr. VP of Generics |
| Mr. Muthusamy Shanmugam MS R.Ph. | Head of R&D, COO of Novitium Operations & Director |
| Ms. Meredith W. Cook | Sr. VP, Gen. Counsel & Corp. Sec. |
| Mr. Chad Gassert | Sr. VP of Corp. Devel. & Strategy |
| Ms. Krista L. Davis | Chief HR Officer |
| Ms. Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 11.8624 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.21 |
| Price-to-Sales TTM: | 2.2566 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 601 |